Related Experiment Video

Updated: Jan 1, 2026

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.9K

TRPV2 channel as a possible drug target for the treatment of heart failure

Yuko Iwata1, Shin Ito2, Shigeo Wakabayashi3

  • 1Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan. yukoiwat@ncvc.go.jp.

Laboratory Investigation; a Journal of Technical Methods and Pathology
|December 21, 2019
PubMed

Insights

Targeting the TRPV2 channel, a key player in calcium overload and heart failure, shows promise for new drug development. Inhibiting TRPV2 improves cardiac function and reduces fibrosis in animal models.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Severe heart failure, often linked to dilated cardiomyopathy, currently has limited treatment options, with heart transplantation being the primary solution.
  • Intracellular calcium (Ca2+) overload is increasingly recognized as a critical factor in the development and progression of heart failure.
  • The transient receptor potential vanilloid 2 (TRPV2) channel, permeable to Ca2+, plays a significant role in maintaining elevated intracellular Ca2+ levels, contributing to heart failure pathogenesis.

Purpose of the Study:

  • To review recent findings on the role of TRPV2 in cardiomyocytes and immune cells during heart failure development.
  • To discuss the therapeutic potential of targeting TRPV2 for heart failure treatment.
  • To highlight the progress in developing TRPV2-specific inhibitors.

Main Methods:

  • Review of recent scientific literature focusing on TRPV2 expression, activation, and function in cardiovascular disease models.
  • Analysis of studies investigating the impact of TRPV2 inhibition on cardiac function, myocardial fibrosis, and overall prognosis in animal models of cardiomyopathy.
  • Examination of research on the involvement of inflammation and immune cells in TRPV2-mediated heart failure.

Main Results:

  • Inhibition of TRPV2 activity has demonstrated significant improvements in cardiac function in animal models of heart failure.
  • TRPV2 inhibition effectively suppresses myocardial fibrosis, a key pathological feature of heart failure.
  • Recent development of TRPV2-specific inhibitors allows for clearer elucidation of its role in heart failure pathology.

Conclusions:

  • TRPV2 is a critical mediator of calcium overload and subsequent heart failure, involving both cardiomyocytes and immune cells.
  • Targeting TRPV2 represents a promising novel therapeutic strategy for treating heart failure.
  • Ongoing drug development efforts focused on TRPV2 inhibitors hold potential for improving patient prognosis.

More Related Videos

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV412:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.5K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.6K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
703
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
751
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
615
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
394